Research
The Epoxyeicosatrienoic Acid Pathway Enhances Hepatic Insulin Signaling and is Repressed in Insulin-Resistant Mouse Liver*

https://doi.org/10.1074/mcp.M115.049064Get rights and content
Under a Creative Commons license
open access

Although it is widely accepted that ectopic lipid accumulation in the liver is associated with hepatic insulin resistance, the underlying molecular mechanisms have not been well characterized.

Here we employed time resolved quantitative proteomic profiling of mice fed a high fat diet to determine which pathways were affected during the transition of the liver to an insulin-resistant state. We identified several metabolic pathways underlying altered protein expression. In order to test the functional impact of a critical subset of these alterations, we focused on the epoxyeicosatrienoic acid (EET) eicosanoid pathway, whose deregulation coincided with the onset of hepatic insulin resistance. These results suggested that EETs may be positive modulators of hepatic insulin signaling. Analyzing EET activity in primary hepatocytes, we found that EETs enhance insulin signaling on the level of Akt. In contrast, EETs did not influence insulin receptor or insulin receptor substrate-1 phosphorylation. This effect was mediated through the eicosanoids, as overexpression of the deregulated enzymes in absence of arachidonic acid had no impact on insulin signaling. The stimulation of insulin signaling by EETs and depression of the pathway in insulin resistant liver suggest a likely role in hepatic insulin resistance. Our findings support therapeutic potential for inhibiting EET degradation.

Cited by (0)

Author contributions: A.S., S.N., H.S., S.M.H., and M.U. designed research; A.S., S.N., and M.K. performed research; T.G. and J.A. contributed new reagents or analytic tools; A.S. wrote the paper; A.I., J.A., S.M.H., and M.U. provided critical discussion and edited the paper.

This work was supported by grants from the German Federal Ministry of Education and Research (BMBF): Grant number 03IS2061B GANI_MED (Greifswald Approach to Individualized Medicine) and a second grant to the German Center for Diabetes Research (DZD e.V.).

This article contains supplemental Figs. S1 to S5 and Tables S1 to S4.

The abbreviations used are:

    HFD

    High fat diet

    CYP

    Cytochrome P450

    DHET

    Dihydroxyeicosatrienoic acid

    EET

    Epoxyeicosatrienoic acid

    FDR

    False discovery rate

    IR

    Insulin receptor

    IRS-1

    Insulin receptor substrate 1

    LFD

    Low fat diet

    MS/MS

    Tandem mass spectrometry

    PPAR

    Peroxisome proliferator-activated receptor

    SRM

    Selected reaction monitoring.